BioNTech SE (BNTX) has a negative trailing P/E of -16.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -5.91%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2017 | -31.4 | 0.00 | -54.59 | 43.69 | - |
| 2018 | -58.7 | 1.31 | 10.58 | 22.08 | - |
| 2019 | -35.7 | -0.12 | 12.95 | 58.84 | - |
| 2020 | 1,033.2 | -9.65 | 11.45 | 32.56 | - |
| 2021 | 5.4 | 0.00 | 4.65 | 2.91 | - |
| 2022 | 3.6 | -0.27 | 1.70 | 1.97 | 1.42% |
| 2023 | 24.7 | -0.27 | 1.13 | 6.02 | - |
| 2024 | -39.8 | 0.23 | 1.36 | 9.62 | - |
| 2025 | -17.9 | -0.29 | 1.02 | 7.10 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.38 | $61.6M | $-85.65M | -139.1% |
| 2018 | $-0.21 | $127.58M | $-48.02M | -37.6% |
| 2019 | $-0.85 | $108.59M | $-179.17M | -165% |
| 2020 | $0.06 | $482.3M | $15.2M | 3.2% |
| 2021 | $39.63 | $18.98B | $10.29B | 54.2% |
| 2022 | $37.77 | $17.31B | $9.43B | 54.5% |
| 2023 | $3.83 | $3.82B | $930.3M | 24.4% |
| 2024 | $-2.77 | $2.75B | $-665.3M | -24.2% |
| 2025 | $-4.51 | $2.76B | $-1.09B | -39.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.35 | $-5.69 – $-3.33 | $2.27B | $2.15B – $2.43B | 11 |
| 2027 | $-4.32 | $-9.66 – $-1.55 | $2.38B | $1.92B – $2.95B | 11 |
| 2028 | $-3.24 | $-9.17 – $-0.73 | $2.76B | $2.26B – $3.39B | 9 |
| 2029 | $-2.48 | $-3.22 – $-1.89 | $2.95B | $2.41B – $3.62B | 3 |
| 2030 | $-0.07 | $-0.08 – $-0.05 | $3.7B | $3.02B – $4.55B | 3 |
